News

Arbor Pharmaceuticals, LLC Announces the Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for the Treatment of Central Precocious Puberty

October 3, 2017

Triptodur™, (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Atlanta, GA, USA and Lausanne, Switzerland – October 3, 2017 – Arbor Pharmaceuticals, LLC, a U.S. based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm…

Read More

Arbor Pharmaceuticals, LLC Launches New Nymalize® (nimodipine) Oral Solution 10 mL (30 mg) Unit Dose for the Treatment of Subarachnoid Hemorrhage

September 20, 2017

Addition of 10 mL (30 mg) unit dose cup provides a ready-to-use dosing option for patients requiring lower doses of nimodipine oral solution Atlanta, GA Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, announced today that Nymalize® (nimodipine) Oral Solution will now be available in a 10 mL (30 mg) unit dose cup. This new packaging…

Read More

New Online Survey Reveals Some Health Care Providers Continue to Recommend OTC Head Lice Treatment Despite Reporting Cases of Ineffectiveness

August 7, 2017

Survey also highlights the need for conversations between parents and HCPs about head lice management and treatment Atlanta, GA Results of the new “Facts of Lice” online survey of 1,000 millennial moms (ages 18-35) and 350 pediatric health care providers released today suggest that some millennial moms may be receiving mixed messages about managing head…

Read More

Arbor Pharmaceuticals, LLC Announces FDA Approval for Triptodur™

June 30, 2017

Atlanta, GA — Arbor Pharmaceuticals announces FDA approval for Triptodur™ Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP) Triptodur™, (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular…

Read More

Xenoport – Notice Of Fundamental Change July 12, 2016

July 12, 2016

Fundamental Change Company Notice

Read More

Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort

July 5, 2016

Atlanta, GA, and Santa Clara, CA — July 5, 2016 — Arbor Pharmaceuticals, LLC (“Arbor”) and XenoPort, Inc. (“XenoPort”) (NASDAQ: XNPT) today announced the successful completion of Arbor’s tender offer to purchase all issued and outstanding shares of XenoPort’s common stock for $7.03 per share in cash. The tender offer expired as scheduled at 11:59…

Read More

Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period

June 16, 2016

Atlanta, GA, and Santa Clara, CA — June 16, 2016 — Arbor Pharmaceuticals, LLC (“Arbor”) and XenoPort, Inc. (“XenoPort”) (NASDAQ: XNPT) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced tender offer by Arbor’s wholly owned subsidiary, AP Acquisition Sub, Inc. (“Acquisition…

Read More

Arbor Pharmaceuticals, LLC Launches Cetylev™

June 13, 2016

Atlanta, GA — Arbor Pharmaceuticals announced today the launch of Cetylev (acetylcysteine) effervescent tablets for oral solution, a new acetaminophen overdose antidote with a lemon-mint taste and smell. Acetaminophen overdose is the most common form of poisoning reported to Poison Control Centers in the United States. According to the National Institute of Health, acetaminophen overdose sends…

Read More

Arbor Pharmaceuticals to Acquire XenoPort

May 23, 2016

Acquisition expands neurology product portfolio  Enhances sales infrastructure Atlanta, GA, and Santa Clara, CA — May 23, 2016 — Arbor Pharmaceuticals, LLC (Arbor) and XenoPort, Inc. (XenoPort) (NASDAQ: XNPT) announced today that they have signed a definitive agreement under which Arbor will acquire XenoPort for $7.03 per share in cash, or a total equity value of…

Read More

Arbor Pharmaceuticals, LLC Announces FDA Approval of Cetylev™

February 9, 2016

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Cetylev (acetylcysteine effervescent tablets for oral solution). Cetylev is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute…

Read More